This clinical trial studies if kilo-voltage cone beam computed tomography (KV-CBCT) and ultrasound imaging works in guiding radiation therapy in patients with prostate, liver, or pancreatic cancer. Computer systems, such as KV-CBCT and ultrasound imaging, allow doctors to create a 3-dimensional picture of the tumor may help in planning radiation therapy and may result in more tumor cells being killed.
PRIMARY OBJECTIVES: I. To investigate the feasibility of combining on-board cone beam computed tomography (CBCT) with ultrasound imaging to overcome the shortcomings of CBCT or ultrasound imaging alone for imaging guided radiotherapy delivery. OUTLINE: Patients undergo ultrasound imaging prior to and during radiation therapy. Patients also undergo kilo-voltage cone beam computed tomography prior to radiation therapy. Update (2021/02/04): Removed secondary outcome "Incidence of Adverse Events Related to the Ultrasound Probe". Per PI: Study initially intended to involve a non-FDA approved probe for use with liver patients but removed this section.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
30
Undergo kilo-voltage cone beam computed tomography
Undergo ultrasound-guided radiation therapy
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Percentage of Ultrasound Images Which Are Clinically Adequate for Treatment Set-up
Percentage of ultrasound images which are clinically adequate for treatment set-up in the judgment of the treating physician
Time frame: Up to 1 year
Number of Participants Able to Have the Ultrasound Probe Attached During the Entire Treatment Course
Proportion of participants able to have the ultrasound probe attached during the entire treatment course
Time frame: Up to 1 year
Percent of Patients Whose Plan Quality Was Not Not Affected in the Presence of the Ultrasound Probe
Quality of plans for patients not affected in the presence of the ultrasound probe, defined as no more than a 2% decrease in tumor coverage, and also no more than a 2% increase in the dose to the most critical normal tissue for that tumor location
Time frame: Up to 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.